Can Ozempic reverse liver disease? New study holds the answer
Why is this big news?
Should everyone with liver disease be on Ozempic?
Increasing coffee consumption may lower severity of non-alcoholic fatty liver: Study
If you've been hearing a lot about Ozempic lately, you're not alone. Once a quiet diabetes drug, it shot to fame as a weight-loss injection. But now, it might be about to earn a new title: a potential game-changer for liver disease. You read that right—Ozempic may not just help you shed pounds, but also reverse serious and common liver conditions.Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist originally designed to manage blood sugar in people with type 2 diabetes. It works by mimicking a hormone that controls hunger, making you feel full faster and eat less. That's how it gained massive popularity for weight loss. But researchers recently discovered another potential benefit that could impact millions—its ability to tackle non-alcoholic steatohepatitis, or NASH.NASH is an advanced form of non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver unrelated to alcohol use. Over time, that fat causes inflammation and liver cell damage, leading to fibrosis (scarring), cirrhosis, or even liver failure. There's currently no approved drug specifically for treating it.This is where Ozempic comes in—and it's not just hype.A new clinical trial, published in the New England Journal of Medicine , revealed that semaglutide can significantly improve liver health in NASH patients.The study was led by Dr Arun Sanyal of the Virginia Commonwealth University (US), and Dr Philip Newsome of King's College London.Researchers followed over 800 people diagnosed with NASH and liver fibrosis. Participants were randomly given either a weekly injection of semaglutide (Ozempic) or a placebo for 72 weeks. The results? Jaw-dropping.More than 62.9% of patients taking semaglutide saw a complete resolution of NASH, compared to just 34.3% in the placebo group. Improvements in both MASH and fibrosis were seen in 32.7 percent of the participants on semaglutide, compared to 16.1 percent of the placebo group.Even better? People also lost weight which is linked to liver health.Until now, patients with NASH have been told the same old advice: lose weight, exercise more, and eat better. While lifestyle changes do work, they're often not enough for people already dealing with fibrosis and significant liver inflammation. Plus, not everyone is able to lose the amount of weight needed to improve liver health.With semaglutide, patients may finally have a real treatment that goes beyond just symptom management.Not so fast. While this is exciting news, semaglutide isn't approved yet specifically for NASH or fatty liver disease—it's currently approved for type 2 diabetes and used for weight loss.Semaglutide, like any drug, it comes with side effects—nausea, vomiting, constipation, and possible risks for pancreatitis or gallbladder issues in some people. So, it's not a universal fix—but it could be a huge step forward for those battling progressive liver disease with few other options, once it gets approved. Don't make any changes without talking to your doctor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Fatty liver reversal with apple cider vinegar? What experts reveal about ACV's effect on your body's largest gland
Synopsis Non-alcoholic fatty liver disease affects a significant portion of the global population, prompting interest in remedies like apple cider vinegar (ACV). While animal studies suggest ACV might reduce liver fat and improve metabolism, human research is limited. Experts recommend ACV as a supplement, not a cure, emphasizing diet, exercise, and medical guidance for managing NAFLD. Fatty liver disease, especially the non-alcoholic kind (NAFLD), is quietly becoming one of the biggest health issues worldwide. According to a TOI report, it affects over 30% of the global population, and in regions like the Americas and Southeast Asia, the figure exceeds 40%. That's worrying. But can something as humble as apple cider vinegar (ACV) help ease the condition? Let's break it Fatty Liver Disease (NAFLD) happens when fat builds up in your liver, without heavy drinking being the cause. It's often linked to being overweight, diabetic, or having a sluggish metabolism. If not managed early, NAFLD can progress to more serious stages like NASH (inflammation), fibrosis, cirrhosis, or even liver cancer. This has led many to turn to home remedies, ACV being one of the most popular. But does it really help your liver?Apple cider vinegar is made by fermenting apple juice into alcohol, and then into acetic acid, the compound responsible for its sharp taste and supposed health often marketed as a metabolism booster, fat burner, and blood sugar regulator. Some claim it can reduce liver fat and support liver function. But what does science actually say? A 2025 study on rainbow trout with NAFLD, as reported by TOI, found that a 2% ACV mix reduced liver fat (steatosis), triglycerides, and key liver enzymes like ALT and AST. But here's the twist, when the dose was doubled to 4%, the condition set of studies on rodents fed high-fat diets showed similar findings. ACV helped reduce liver fat, improve insulin resistance, and lower glucose levels. In one experiment, liver fat levels dropped from 56% to 20%.Researchers believe acetic acid may promote fat-burning and ease metabolic stress. However, all these results come from animal studies, not research is still limited. A 2021 review, quoted by TOI, suggested ACV could lower cholesterol and fasting blood sugar, both helpful for those with NAFLD. But there's no strong proof yet of a direct impact on liver fat in short: promising, but far from perks May support blood sugar and fat metabolism Could assist in weight loss when used with diet and exercise Might improve some metabolic markers over time But here's the catch Too much ACV can damage tooth enamel, cause low potassium, and upset your stomach It may interact badly with diabetes or blood pressure medications Most experts advise no more than 1–2 tablespoons a day, diluted in water Health professionals, as quoted by TOI, warn against treating ACV as a 'cure'. It's a supplement, not a substitute for actual medical treatment or lifestyle changes. Use raw, unfiltered ACV (look for 'the mother') Dilute properly: Mix 1 tablespoon in a full glass of water Drink after meals to avoid acid reflux Rinse your mouth or use a straw to protect your teeth Watch for side effects like bloating or discomfort Talk to your doctor if you're on any medication While ACV may offer some small benefits for metabolism, it's not a cure-all for fatty liver. The best way to reverse NAFLD is through a balanced diet, regular exercise, and guidance from your healthcare provider. Apple cider vinegar might play a supporting role, but it's definitely not the hero of the story. Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Time of India
2 hours ago
- Time of India
Fatty liver reversal with apple cider vinegar? What experts reveal about ACV's effect on your body's largest gland
Fatty liver disease, especially the non-alcoholic kind (NAFLD), is quietly becoming one of the biggest health issues worldwide. According to a TOI report, it affects over 30% of the global population, and in regions like the Americas and Southeast Asia, the figure exceeds 40%. That's worrying. But can something as humble as apple cider vinegar (ACV) help ease the condition? Let's break it down. What is NAFLD and why should you care? Non-Alcoholic Fatty Liver Disease (NAFLD) happens when fat builds up in your liver, without heavy drinking being the cause. It's often linked to being overweight, diabetic, or having a sluggish metabolism. If not managed early, NAFLD can progress to more serious stages like NASH (inflammation), fibrosis, cirrhosis, or even liver cancer. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence Public Policy Product Management healthcare Cybersecurity MCA Others Design Thinking CXO Data Science PGDM MBA Project Management Degree Finance Healthcare Leadership Digital Marketing Data Analytics Operations Management Technology others Management Data Science Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details This has led many to turn to home remedies, ACV being one of the most popular. But does it really help your liver? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo What does research say about Apple Cider Vinegar? Apple cider vinegar is made by fermenting apple juice into alcohol, and then into acetic acid, the compound responsible for its sharp taste and supposed health perks. It's often marketed as a metabolism booster, fat burner, and blood sugar regulator. Some claim it can reduce liver fat and support liver function. But what does science actually say? Live Events Animal studies suggest it might help A 2025 study on rainbow trout with NAFLD, as reported by TOI, found that a 2% ACV mix reduced liver fat (steatosis), triglycerides, and key liver enzymes like ALT and AST. But here's the twist, when the dose was doubled to 4%, the condition worsened. Another set of studies on rodents fed high-fat diets showed similar findings. ACV helped reduce liver fat, improve insulin resistance, and lower glucose levels. In one experiment, liver fat levels dropped from 56% to 20%. Researchers believe acetic acid may promote fat-burning and ease metabolic stress. However, all these results come from animal studies, not humans. And what about human trials? Human-based research is still limited. A 2021 review, quoted by TOI, suggested ACV could lower cholesterol and fasting blood sugar, both helpful for those with NAFLD. But there's no strong proof yet of a direct impact on liver fat in humans. In short: promising, but far from conclusive. ACV: Worth a shot or not? Possible perks May support blood sugar and fat metabolism Could assist in weight loss when used with diet and exercise Might improve some metabolic markers over time But here's the catch Too much ACV can damage tooth enamel, cause low potassium, and upset your stomach It may interact badly with diabetes or blood pressure medications Most experts advise no more than 1–2 tablespoons a day, diluted in water Health professionals, as quoted by TOI, warn against treating ACV as a 'cure'. It's a supplement, not a substitute for actual medical treatment or lifestyle changes. How to use ACV the safe way Use raw, unfiltered ACV (look for 'the mother') Dilute properly: Mix 1 tablespoon in a full glass of water Drink after meals to avoid acid reflux Rinse your mouth or use a straw to protect your teeth Watch for side effects like bloating or discomfort Talk to your doctor if you're on any medication ACV isn't a magic potion While ACV may offer some small benefits for metabolism, it's not a cure-all for fatty liver. The best way to reverse NAFLD is through a balanced diet, regular exercise, and guidance from your healthcare provider. Apple cider vinegar might play a supporting role, but it's definitely not the hero of the story.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Pharma Inc gears up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
